禾元生物(688765)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688765 禾元生物

已收盘 02-13 15:00:00

{"stockData":{"symbol":"688765","market":"SH","secType":"STK","nameCN":"禾元生物","latestPrice":72.04,"timestamp":1770966000000,"preClose":72.92,"halted":0,"volume":954589,"delay":0,"changeRate":-0.0121,"floatShares":40978800,"shares":358000000,"eps":-0.4499,"marketStatus":"已收盘","change":-0.88,"latestTime":"02-13 15:00:00","open":72.89,"high":73.33,"low":72.04,"amount":69311800,"amplitude":0.0177,"askPrice":72.05,"askSize":8,"bidPrice":72.04,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-0.4499,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771896600000},"marketStatusCode":5,"adr":0,"adjPreClose":72.92,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770946200000,1770953400000],[1770958800000,1770966000000]],"highLimit":80.21,"lowLimit":65.63,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":357500000,"isCdr":false,"pbRate":51.82,"roa":"--","roe":"--","epsLYR":-0.5647,"committee":0.225296,"marketValue":25754000000,"turnoverRate":0.0233,"status":1,"afterMarket":{"amount":14408,"volume":200,"close":72.04,"buyVolume":0,"sellVolume":0,"time":1770968037558,"indexStatus":"已收盘 02-13 15:30:00","preClose":72.92},"floatMarketCap":2952000000},"requestUrl":"/m/hq/s/688765","defaultTab":"news","newsList":[{"id":"2609568129","title":"禾元生物：四年累亏超6亿，多风险交织下的“未盈利”样本","url":"https://stock-news.laohu8.com/highlight/detail?id=2609568129","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609568129?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:13","pubTimestamp":1770365580,"startTime":"0","endTime":"0","summary":"　　作为一家通过科创板第五套上市标准登陆资本市场的未盈利生物医药企业，禾元生物自上市以来便备受关注。然而，随着近期公司发布2025年业绩预告，其持续扩大的亏损、紧绷的现金流、核心产品商业化存疑以及信息披露的争议，正使其成为观察未盈利科创企业生存现状的一个典型样本。　　禾元生物近日披露，预计2025年归母净利润亏损1.43亿元至1.67亿元，加上此前三年累计亏损已超4.8亿元，这意味着公司四年来累计亏损将突破6亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-02-06/doc-inhkwnki2086633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688765","BK0239"],"gpt_icon":0},{"id":"2607746969","title":"股市必读：禾元生物（688765）预计2025年全年扣除后营业收入:4,500万元至5,000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607746969","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607746969?lang=zh_cn&edition=full","pubTime":"2026-01-29 01:06","pubTimestamp":1769619972,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，禾元生物报收于79.6元，下跌4.1%，换手率5.81%，成交量2.38万手，成交额1.93亿元。业绩披露要点业绩预告禾元生物发布业绩预告，预计2025年全年归属净利润亏损1.43亿元至1.67亿元；预计全年营业收入为4500万元至5000万元，同比增长78.46%至98.29%；扣除后营业收入为4,500万元至5,000万元；扣非后净利润预计亏损1.62亿元至1.91亿元。预计2025年年度实现营业收入4,500万元到5,000万元，同比增长78.46%到98.29%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900000741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765"],"gpt_icon":0},{"id":"2606969267","title":"禾元生物(688765.SH)：2025年预亏1.43亿元至1.67亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606969267","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606969267?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:37","pubTimestamp":1769589422,"startTime":"0","endTime":"0","summary":"格隆汇1月28日丨禾元生物公布，经财务部门初步测算，预计2025年年度实现利润总额-16,700万元到-14,300万元，预计2025年年度实现归属于母公司所有者的净利润-16,700万元到-14,300万元。预计2025年年度实现营业收入4,500万元到5,000万元，同比增加78.46%到98.29%，扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入为4,500万元到5,000万元。受上述因素共同影响，报告期内公司整体仍处于业绩亏损状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260128/31979451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688765"],"gpt_icon":0},{"id":"2606929764","title":"吉林敖东：公司暂无对禾元生物的投资计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2606929764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606929764?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:45","pubTimestamp":1769413518,"startTime":"0","endTime":"0","summary":"证券之星消息，吉林敖东01月26日在投资者关系平台上答复投资者关心的问题。或者是继续加大对辽宁成大的投资计划？谢谢吉林敖东回复：尊敬的投资者：您好！公司暂无对禾元生物的投资计划。截至目前，公司及子公司延边药业合计持有辽宁成大103,625,476股，占辽宁成大总股本的6.77%，后续若有达到信息披露标准的事项将及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600015104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0086","BK0012","BK0201","000623","BK0188","BK0074","688765"],"gpt_icon":0},{"id":"2605580127","title":"贝达药业：投资禾元生物公允价值变动不影响净利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2605580127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605580127?lang=zh_cn&edition=full","pubTime":"2026-01-21 12:33","pubTimestamp":1768969988,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘 我司投资的禾元生物，按最近禾元生物市值，权益法计算，对我司净利润将带来20-25亿的增加。请问如果按权益法计算，我司净利润将暴增700％。为什么我司还不发布业绩预告？贝达药业回复：您好！公司对武汉禾元生物科技股份有限公司的投资计入其他权益工具投资科目核算，根据企业会计准则有关规定，将其公允价值变动计入其他综合收益科目，不影响公司净利润。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100017326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","300558"],"gpt_icon":0},{"id":"2592915894","title":"禾元生物（688765）披露关于持股5%以上股东部分股份质押的公告，12月17日股价上涨0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915894","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592915894?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:04","pubTimestamp":1765980262,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，禾元生物报收于72.09元，较前一交易日上涨0.12%，最新总市值为257.72亿元。该股当日开盘71.95元，最高72.4元，最低70.57元，成交额达1.44亿元，换手率为4.91%。公司近日发布公告称，持股5%以上的股东上海同盛永盈企业管理中心持有公司股份20,084,400股，占公司总股本的5.62%。本次质押股份11,730,000股，占其持股总数的58.40%，占公司总股本的3.28%。质押股份为限售股，质权人为湖北省铁路发展基金有限责任公司，质押融资用于自身资金需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700038978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688765"],"gpt_icon":0},{"id":"2590850425","title":"禾元生物（688765）公司公告披露购买董高责任险议案获股东会通过，12月12日股价下跌3.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590850425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590850425?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:03","pubTimestamp":1765548220,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，禾元生物报收于77.54元，较前一交易日下跌3.68%，最新总市值为277.21亿元。近日，武汉禾元生物科技股份有限公司召开2025年第三次临时股东会，会议审议通过了《关于购买董高责任险的议案》。公告显示，出席会议的股东及代理人共655人，代表有表决权股份110,750,139股，占公司总表决权股份的34.9133%。该议案为普通决议议案，已获得出席股东所持有效表决权过半数通过，关联股东杨代常回避表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200040550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","BK0239"],"gpt_icon":0},{"id":"2588701460","title":"【机构调研记录】鹏扬基金调研禾元生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701460?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:05","pubTimestamp":1764633942,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月1日披露的机构调研信息，鹏扬基金近期对1家上市公司进行了调研，相关名单如下：1）禾元生物 调研纪要：公司计划开展HY1001全球多中心III期临床，拓展至人血白蛋白全部适应症，并拟申报中美欧上市。鹏扬基金成立于2016年，截至目前，资产管理规模1453.24亿元，排名49/211；资产管理规模1249.96亿元，排名41/211；管理公募基金数183只，排名39/211；旗下公募基金经理26人，排名53/211。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200003778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","BK0239"],"gpt_icon":0},{"id":"2584664899","title":"卫光生物：暂未与禾元生物开展合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2584664899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584664899?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:18","pubTimestamp":1763367501,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物11月17日在投资者关系平台上答复投资者关心的问题。公司未来在利用动植物大规模生产重组人白蛋白有哪些布局？公司目前暂未与禾元生物开展合作，公司聚焦血液制品领域，坚持技术驱动产品研发，对新技术秉持开放拥抱态度，并密切关注市场动态和行业前沿技术与应用，不断提高自身综合竞争实力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700019970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","002880","BK0239","BK0046"],"gpt_icon":0},{"id":"2582865078","title":"每周股票复盘：禾元生物（688765）近5日三次登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2582865078","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582865078?lang=zh_cn&edition=full","pubTime":"2025-11-09 01:08","pubTimestamp":1762621692,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，禾元生物报收于94.96元，较上周的123.55元下跌23.14%。本周，禾元生物11月4日盘中最高价报131.02元。11月7日盘中最低价报94.5元。禾元生物当前最新总市值339.48亿元，在生物制品板块市值排名10/51，在两市A股市值排名554/5166。沪深交易所2025年11月5日公布的交易公开信息显示，禾元生物因有价格涨跌幅限制的日换手率达到30%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","BK0239"],"gpt_icon":0},{"id":"2581675008","title":"11月7日禾元生物（688765）龙虎榜数据：游资余哥上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2581675008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581675008?lang=zh_cn&edition=full","pubTime":"2025-11-07 17:18","pubTimestamp":1762507137,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年11月7日公布的交易公开信息显示，禾元生物因有价格涨跌幅限制的日换手率达到30%的前五只证券登上龙虎榜。此次是近5个交易日内第3次上榜。截至2025年11月7日收盘，禾元生物报收于94.96元，下跌7.09%，换手率30.81%，成交量12.63万手，成交额12.49亿元。从龙虎榜公布的当日买卖数据来看，余哥等知名游资榜上有名。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700027382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688765"],"gpt_icon":0},{"id":"2581424477","title":"11月5日禾元生物（688765）龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2581424477","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581424477?lang=zh_cn&edition=full","pubTime":"2025-11-05 17:29","pubTimestamp":1762334940,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年11月5日公布的交易公开信息显示，禾元生物因有价格涨跌幅限制的日换手率达到30%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年11月5日收盘，禾元生物报收于112.0元，下跌12.55%，换手率45.34%，成交量18.58万手，成交额22.06亿元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500029813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","BK0239"],"gpt_icon":0},{"id":"2579464989","title":"禾元生物盘中涨近12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579464989","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579464989?lang=zh_cn&edition=full","pubTime":"2025-10-29 10:42","pubTimestamp":1761705720,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）10月29日，禾元生物（688765）低开高走，盘中一度涨近12%。　　交易行情显示，禾元生物10月29日低开1.2%，开盘价为90.01元/股，盘中最高触及102.18元/股。截至北京商报记者发稿，禾元生物报100.2元/股，涨幅为9.99%。　　值得一提的是，禾元生物于10月28日上市，上市首日，公司股票大幅收涨213.49%。（文章来源：北京商报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-29/doc-infvpqhp3438615.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-29/doc-infvpqhp3438615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688765"],"gpt_icon":0},{"id":"2578880209","title":"禾元生物科创板上市：大涨203%市值315亿 湖北再增一家IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2578880209","media":"雷递网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578880209?lang=zh_cn&edition=full","pubTime":"2025-10-28 12:54","pubTimestamp":1761627249,"startTime":"0","endTime":"0","summary":"武汉禾元生物科技股份有限公司（简称：“禾元生物”，Healthgen Biotechnology Corp.）今日在科创板上市，募资总额为26亿元。禾元生物开盘价为88元，较发行价上涨203%；截至今日午盘，公司市值约314.74亿元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20251028/6389725283822938266284061.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20251028/6389725283822938266284061.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n31586/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["688765","159982"],"gpt_icon":0},{"id":"2576945049","title":"每周股票复盘：华熙生物（688363）战略投资禾元生物获配68.82万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2576945049","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576945049?lang=zh_cn&edition=full","pubTime":"2025-10-19 03:36","pubTimestamp":1760816171,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，华熙生物报收于53.23元，较上周的55.78元下跌4.57%。本周，华熙生物10月16日盘中最高价报56.03元。本周关注点来自机构调研要点：华熙生物以2000万元参与禾元生物战略配售，获配68.82万股。本次配售完成后，公司将成为禾元生物的战略股东。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","688363","BK0239","688765"],"gpt_icon":0},{"id":"2575236915","title":"A股申购 | 禾元生物(688765.SH)开启申购 共有8个在研药品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2575236915","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575236915?lang=zh_cn&edition=full","pubTime":"2025-10-14 06:30","pubTimestamp":1760394604,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月14日，禾元生物开启申购，发行价格为29.06元/股，申购上限为1.4万股，属于上交所，国泰海通证券为其保荐机构。目前公司尚无获批上市的药品，尚未盈利。资料显示，禾元生物已于2025年5月底与美国FDA开展HY1001国际多中心III期临床试验设计沟通会议，FDA已同意在完成国际多中心III期临床研究，并达到预期结果后，HY1001可获批血浆来源的人血清白蛋白所有现行适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399300","159982","688765"],"gpt_icon":0},{"id":"2569716093","title":"年内首单“先H后A”上会公司来了：百奥赛图业绩大增增长率“负披露”引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2569716093","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569716093?lang=zh_cn&edition=full","pubTime":"2025-09-23 22:37","pubTimestamp":1758638228,"startTime":"0","endTime":"0","summary":"“国内模式动物三巨头”将齐聚A股","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/f6aee5aa-438a-4ad7-a4b4-6104f0603bc2.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/f6aee5aa-438a-4ad7-a4b4-6104f0603bc2.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3756129","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3756129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["688765"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771144879935,"stockEarnings":[{"period":"1week","weight":-0.0169},{"period":"1month","weight":-0.1555},{"period":"3month","weight":-0.1625},{"period":"6month","weight":1.479},{"period":"ytd","weight":0.0424}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉禾元生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47138人(较上一季度增加35077.61%)","perCapita":"869股","listingDate":"2025-10-28","address":"湖北省武汉市江夏区武汉东湖新技术开发区神墩五路268号","registeredCapital":"35750万元","survey":"　　武汉禾元生物科技股份有限公司一直致力于运用水稻胚乳细胞重组蛋白表达技术平台（水稻胚乳细胞生物反应器平台）进行植物源重组人血清白蛋白等产品的研发、生产及销售。公司产品主要包括药品、药用辅料以及科研试剂。公司是湖北省分子医药工程技术研究中心、湖北省企业技术中心和武汉国家生物产业基地蛋白质纯化中心；承担了国家“重大新药创制”科技重大专项等国家级科研项目。截至本招股意向书签署日，发行人拥有21项境内发明专利与62项境外发明专利，合计17项应用于公司主营业务并能够产业化的发明专利。公司拥有自主知识产权的“水稻胚乳细胞生物反应器及其应用”于2013年荣获国家技术发明二等奖。","listedPrice":29.06},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"禾元生物(688765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供禾元生物(688765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"禾元生物,688765,禾元生物股票,禾元生物股票老虎,禾元生物股票老虎国际,禾元生物行情,禾元生物股票行情,禾元生物股价,禾元生物股市,禾元生物股票价格,禾元生物股票交易,禾元生物股票购买,禾元生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"禾元生物(688765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供禾元生物(688765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}